The new era of MASH pharmacotherapy: a comprehensive review of FDA-approved and emerging agents
{{output}}
Background: Metabolic dysfunction-associated steatohepatitis (MASH), formerly nonalcoholic steatohepatitis (NASH), is a progressive liver disease and a leading cause of cirrhosis and liver-related mortality worldwide, affecting a... ...
